Menu Back to DIAmond

How to Register

Register Online for DIA Europe 2018


Register Online
Pay with Credit Card
or by Invoice

Registration Questions


09:00AM – 05:30PM


Send Email

DIAmond Sessions

Conversations on Today's Priorities

Each day join a panel of thought-leaders on global, interdisciplinary, cutting-edge topics about the future of drug development and how these issues affect you. These combined flagship sessions bring together innovators from industry, academia, government agencies and patient advocates to have a conversation on today’s priorities.

Explore the 10 DIAmond Sessions for 2018

  • DIA Europe 2018 Regulatory Science IconEuropean Regulatory Town Hall Meeting

    17 April, 11:00 - 12:30

    The Regulatory Townhall is a must-attend for anyone who wants to hear the recent developments and future direction of the EU regulatory network. Come listen to the latest issues from a panel consisting of senior leadership from the EMA and National Competent Authorities (NCA).
    Session in development.

  • DIA Europe 2018 Value Access IconPayer Town Hall Meeting: Fair Pricing

    17 April, 11:00 - 12:30

    Discussions in health care are moving from innovation and science to economics and affordability. Due to current developments in technology (many new, effective products), combined with high prices demanded by companies, the sustainability of health care systems is threatened. Expensive treatments for some patients displace effective treatments for other patients: the concept of solidarity, on which our health care systems are build, is disappearing. In this session we will explore the possibility of Fair Pricing by turning the process upside down: Can society decide the price for the products, treatments and healthcare they want access to? If so, can manufacturers deliver these products at a price the health care system is willing and able to pay?

  • DIA Europe 2018 Pharmacovigilance IconInternational Pharmacovigilance

    17 April, 11:00 - 12:30

    Pharmacovigilance is of increasing focus and importance internationally, Although welcome, huge variations in approach, legislative maturity, resource and fast-moving change are a challenge for all. We all have a responsibility to support development of effective pharmacovigilance systems globally to protect patients and support medicine delivery. With multiple activities worldwide and scarce resources, important key stakeholders must understand each other’s activities and support each other to achieve the same ultimate objectives. A panel of experts (stakeholders, regulators, industry, emerging market) will discuss the latest issues.
    Session in development.

  • DIA Europe 2018 Value Access IconRealising the Potential of Future Biomedical Innovation

    17 April, 14:00 - 15:30

    The Role of Intensified EU Cooperation on HTAs
    In light of the evolving medicine development paradigm and the limited resources of national HTA agencies it becomes increasingly apparent that the currently national and sub-national approach to the assessment of relative clinical efficacy of medicines will unlikely allow EU patients to optimally realize the potential benefits of the evolving drug development paradigm and future biomedical innovation. Panelists will present their perspectives on how to further advance the EU cooperation between national HTA agencies, EMA and other stakeholders on the assessment of the relative efficacy of medicines.

  • DIA Europe 2018 Pharmacovigilance IconWill Big Data Change Drug Development's Approach?

    17 April, 14:00 - 15:30

    Will Big Data enable change in clinical development and how? Hear the views of senior leaders from regulatory and pharmaceutical organisations will share their view on the impact of Big Data in clinical development, submission and reimbursement.

  • DIA Europe 2018 Regulatory Science IconNCA Showcase

    17 April, 14:00 - 15:30

    This DIAmond session gives the floor to the National Competent Authorities (NCA) to discuss their local progress, burning topics, and stakeholder engagement. It is developed by Heads of Medicines Agencies working groups and gives in-depth views on the successes and challenges at the national level.
    Session in development.

  • DIA Europe 2018 Pharmacovigilance IconEvidence Generation in Medicines Development for Fragmented and Rare Patient Populations

    18 April, 08:30 - 10:00

    This session will focus on new innovative ways of evidence generation, such as single arm trials (Phase 1b), indirect comparisons (historic controls) and the impact of next generation sequencing on evidence generation. To discuss these complex topics, regulators, HTA bodies, patients and industry will review challenges and opportunities on the basis of case studies. The session will touch but not focus on real world data and as such complement other sessions on that theme.
    Session in development.

  • DIA Europe 2018 Regulatory Science IconExploring Use of Artificial Intelligence

    18 April, 08:30 - 10:00

    Trust in Technology, or Trust in Each Other?
    This session will examine how innovative technologies, including artificial intelligence and machine learning can help drug developers and regulators understand and navigate the growing volume and complexity of data on the regulatory and clinical development environment.

  • DIA Europe 2018 Patient Engagement IconPatient-Centricity Beyond the Talk

    18 April, 08:30 - 10:00

    Patient-centricity is the talk of the day - but what does successful and systematic implementation really look like? What works? What doesn’t? And why? Join us for an in-depth discussion about patient-centricity with thought leaders in their respective fields of work.

  • DIA Europe 2018 Regulatory Science IconBrexit

    19 April, 14:30 - 16:00

    This session will discuss EMA transition period, business continuity, future of EU regulatory network, MHRA prospects and various aspects that anyone working with the EMA or having a product on the UK market wants to get insights on.